256 related articles for article (PubMed ID: 31423576)
21. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
22. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
23. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
24. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR; Dillon H; Sinha R; Shenoy PJ; Levy D; Dawson K; Hirata JH; Flowers CR
Ann Oncol; 2013 Feb; 24(2):441-448. PubMed ID: 23041589
[TBL] [Abstract][Full Text] [Related]
25. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
26. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
28. FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma.
Mihaljevic B; Jelicic J; Andjelic B; Antic D; Markovic O; Petkovic I; Jovanovic MP; Trajkovic G; Bila J; Djurasinovic V; Sretenovic A; Vukovic V; Smiljanic M; Balint MT
Int J Hematol; 2016 Dec; 104(6):692-699. PubMed ID: 27714586
[TBL] [Abstract][Full Text] [Related]
29. Life expectancy of young adults with follicular lymphoma.
Conconi A; Lobetti-Bodoni C; Montoto S; Lopez-Guillermo A; Coutinho R; Matthews J; Franceschetti S; Bertoni F; Moccia A; Rancoita PM; Gribben J; Cavalli F; Gaidano G; Lister TA; Montserrat E; Ghielmini M; Zucca E
Ann Oncol; 2015 Nov; 26(11):2317-22. PubMed ID: 26362567
[TBL] [Abstract][Full Text] [Related]
30. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
31. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].
Wang N; Xu PP; Wang L; Cheng S; Zhao WL; Sun HP
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):46-51. PubMed ID: 30704228
[No Abstract] [Full Text] [Related]
33. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
34. Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.
Boughan KM; Caimi PF
Curr Oncol Rep; 2019 May; 21(7):63. PubMed ID: 31119485
[TBL] [Abstract][Full Text] [Related]
35. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
36. Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model.
Andjelić B; Todorović-Balint M; Antić D; Bila J; Djurašinović V; Mihaljević B
Vojnosanit Pregl; 2015 Jan; 72(1):26-32. PubMed ID: 26043587
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.
Heilgeist A; McClanahan F; Ho AD; Witzens-Harig M
Cancer; 2013 Jan; 119(1):99-106. PubMed ID: 22736411
[TBL] [Abstract][Full Text] [Related]
38. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
39. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
40. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
